Business
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention
SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, was featured on CW39's H-Town Live, where he discussed the Company's pioneering efforts in breast cancer prevention.\n\n \n \n \n \n \n \n\n \nDuring the segment, Dr. Kumar highlighted Anixa's groundbreaking research in developing a novel breast cancer vaccine in collaboration with the Cleveland Clinic. The vaccine, currently in clinical trials, aims to prevent triple-negative breast cancer (TNBC), the most aggressive and difficult-to-treat form of the disease. By targeting a specific protein found in TNBC cells but absent in normal breast tissue, the vaccine seeks to stimulate the immune system to recognize and eliminate cancer cells before they can develop into full-blown tumor mass.\n\"We are dedicated to advancing science that can fundamentally change the way we approach breast cancer,\" said Dr. Kumar during the interview. \"Our vaccine is designed to prevent the disease before it starts, potentially eliminating the need for invasive treatments such as chemotherapy and surgery in the future.\"\nThe discussion also addressed the broader impact of Anixa's research on the field of oncology, as well as the importance of continued innovation in cancer prevention.\nTo watch Dr. Amit Kumar's full interview on H-Town Live, please visit: https://www.youtube.com/watch?v=b8r5mJsJn74.\nFor more information about Anixa Biosciences and its ongoing clinical trials, please visit www.anixa.com.\nAbout Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus ...